Cover Image
Market Research Report
Product code 
1059177

Global Orphan Drugs Market Research Report 2022

Published: | QYResearch | 96 Pages | Delivery time: 2-3 business days

Price

Back to Top
Global Orphan Drugs Market Research Report 2022
Published: February 18, 2022
QYResearch
Content info: 96 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

Market Analysis and Insights:

The global Orphan Drugs market size is projected to reach US$ 269.15 Billion by 2028, from US$ 139.17 million in 2021, at a CAGR of 9.86% during 2022-2028.

Fully considering the economic change by this health crisis, Oncology accounting for 63.30% of the Orphan Drugs global market in 2021, is projected to value US$ 172.77 Billion by 2028, growing at a revised 10.05% CAGR in the post-COVID-19 period. While Adult segment is altered to an 10.01% CAGR throughout this forecast period.

China Orphan Drugs market size is valued at US$ 19.06 Billion in 2021, while the North America and Europe Orphan Drugs are US$ 57.07 Billion and US$ 26.14 Billion, severally. The proportion of the North America is 41.01% in 2021, while China and Europe are 13.70% and 18.80% respectively, and it is predicted that China proportion will reach 14.14% in 2028, trailing a CAGR of 10.28% through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR 9.89%, 9.10%, and 9.56% respectively for the next 6-year period. As for the Europe Orphan Drugs landscape, Germany is projected to reach US$ 12.17 Billion by 2028 trailing a CAGR of 10.11% over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Orphan Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Orphan Drugs market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Orphan Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Orphan Drugs market.

Scope and Market Size:

Orphan Drugs market is segmented by players, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Orphan Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2017-2028.

By Company

  • Bristol-Myers Squibb
  • Roche
  • Novartis
  • Johnson & Johnson
  • Pfizer
  • Amgen
  • Sanofi
  • AstraZeneca
  • Takeda
  • Vertex Pharmaceuticals
  • AbbVie
  • Biogen
  • Eli Lilly

Segment by Type

  • Oncology
  • Pulmonary
  • Neurology
  • Hematology
  • Endocrinology
  • Cardio-vascular
  • Metabolic Disorders
  • Other

Segment by Application

  • Baby & Child
  • Teenager
  • Adult
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • South America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

TABLE OF CONTENTS

1 REPORT OVERVIEW

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Orphan Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
    • 1.2.2 Oncology
    • 1.2.3 Pulmonary
    • 1.2.4 Neurology
    • 1.2.5 Hematology
    • 1.2.6 Endocrinology
    • 1.2.7 Cardio-vascular
    • 1.2.8 Metabolic Disorders
  • 1.3 Market by Application
    • 1.3.1 Global Orphan Drugs Market Share by Application: 2017 VS 2021 VS 2028
    • 1.3.2 Baby & Child
    • 1.3.3 Teenager
    • 1.3.4 Adult
    • 1.3.5 Old People
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 GLOBAL GROWTH TRENDS

  • 2.1 Global Orphan Drugs Market Perspective (2017-2028)
  • 2.2 Orphan Drugs Growth Trends by Region
    • 2.2.1 Orphan Drugs Market Size by Region: 2017 VS 2021 VS 2028
    • 2.2.2 Orphan Drugs Historic Market Size by Region (2017-2022)
    • 2.2.3 Orphan Drugs Forecasted Market Size by Region (2023-2028)
  • 2.3 Orphan Drugs Market Dynamics
    • 2.3.1 Orphan Drugs Industry Trends
    • 2.3.2 Orphan Drugs Market Drivers
    • 2.3.3 Orphan Drugs Market Challenges
    • 2.3.4 Orphan Drugs Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

  • 3.1 Global Top Orphan Drugs Players by Revenue
    • 3.1.1 Global Top Orphan Drugs Players by Revenue (2017-2022)
    • 3.1.2 Global Orphan Drugs Revenue Market Share by Players (2017-2022)
  • 3.2 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Orphan Drugs Revenue
  • 3.4 Global Orphan Drugs Market Concentration Ratio
    • 3.4.1 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs Revenue in 2021
  • 3.5 Orphan Drugs Key Players Head office and Area Served
  • 3.6 Key Players Orphan Drugs Product Solution and Service
  • 3.7 Mergers & Acquisitions, Expansion Plans

4 ORPHAN DRUGS BREAKDOWN DATA BY TYPE

  • 4.1 Global Orphan Drugs Historic Market Size by Type (2017-2022)
  • 4.2 Global Orphan Drugs Forecasted Market Size by Type (2023-2028)

5 ORPHAN DRUGS BREAKDOWN DATA BY APPLICATION

  • 5.1 Global Orphan Drugs Historic Market Size by Application (2017-2022)
  • 5.2 Global Orphan Drugs Forecasted Market Size by Application (2023-2028)

6 NORTH AMERICA

  • 6.1 North America Orphan Drugs Market Size (2017-2028)
  • 6.2 North America Orphan Drugs Market Size by Country (2017-2022)
  • 6.3 North America Orphan Drugs Market Share by Country (2023-2028)
  • 6.4 United States
  • 6.5 Canada

7 EUROPE

  • 7.1 Europe Orphan Drugs Market Size (2017-2028)
  • 7.2 Europe Orphan Drugs Market Size by Country (2017-2022)
  • 7.3 Europe Orphan Drugs Market Size by Country (2023-2028)
  • 7.4 Germany
  • 7.5 France
  • 7.6 U.K.
  • 7.7 Italy
  • 7.8 Russia
  • 7.9 Nordic Countries

8 ASIA-PACIFIC

  • 8.1 Asia-Pacific Orphan Drugs Market Size (2017-2028)
  • 8.2 Asia-Pacific Orphan Drugs Market Size by Region (2017-2022)
  • 8.3 Asia-Pacific Orphan Drugs Market Size by Region (2023-2028)
  • 8.4 China
  • 8.5 Japan
  • 8.6 South Korea
  • 8.7 Southeast Asia
  • 8.8 India
  • 8.9 Australia

9 LATIN AMERICA

  • 9.1 Latin America Orphan Drugs Market Size (2017-2028)
  • 9.2 Latin America Orphan Drugs Market Size by Country (2017-2022)
  • 9.3 Latin America Orphan Drugs Market Size by Country (2023-2028)
  • 9.4 Mexico
  • 9.5 Brazil

10 MIDDLE EAST & AFRICA

  • 10.1 Middle East & Africa Orphan Drugs Market Size (2017-2028)
  • 10.2 Middle East & Africa Orphan Drugs Market Size by Country (2017-2022)
  • 10.3 Middle East & Africa Orphan Drugs Market Size by Country (2023-2028)
  • 10.4 Turkey
  • 10.5 Saudi Arabia
  • 10.6 UAE

11 KEY PLAYERS PROFILES

  • 11.1 Bristol-Myers Squibb
    • 11.1.1 Bristol-Myers Squibb Company Details
    • 11.1.2 Bristol-Myers Squibb Business Overview
    • 11.1.3 Bristol-Myers Squibb Orphan Drugs Introduction
    • 11.1.4 Bristol-Myers Squibb Revenue in Orphan Drugs Business (2017-2022)
    • 11.1.5 Bristol-Myers Squibb Recent Development
  • 11.2 Roche
    • 11.2.1 Roche Company Details
    • 11.2.2 Roche Business Overview
    • 11.2.3 Roche Orphan Drugs Introduction
    • 11.2.4 Roche Revenue in Orphan Drugs Business (2017-2022)
    • 11.2.5 Roche Recent Development
  • 11.3 Novartis
    • 11.3.1 Novartis Company Details
    • 11.3.2 Novartis Business Overview
    • 11.3.3 Novartis Orphan Drugs Introduction
    • 11.3.4 Novartis Revenue in Orphan Drugs Business (2017-2022)
    • 11.3.5 Novartis Recent Development
  • 11.4 Johnson & Johnson
    • 11.4.1 Johnson & Johnson Company Details
    • 11.4.2 Johnson & Johnson Business Overview
    • 11.4.3 Johnson & Johnson Orphan Drugs Introduction
    • 11.4.4 Johnson & Johnson Revenue in Orphan Drugs Business (2017-2022)
  • 11.5 Pfizer
    • 11.5.1 Pfizer Company Details
    • 11.5.2 Pfizer Business Overview
    • 11.5.3 Pfizer Orphan Drugs Introduction
    • 11.5.4 Pfizer Revenue in Orphan Drugs Business (2017-2022)
    • 11.5.5 Pfizer Recent Development
  • 11.6 Amgen
    • 11.6.1 Amgen Company Details
    • 11.6.2 Amgen Business Overview
    • 11.6.3 Amgen Orphan Drugs Introduction
    • 11.6.4 Amgen Revenue in Orphan Drugs Business (2017-2022)
    • 11.6.5 Amgen Recent Development
  • 11.7 Sanofi
    • 11.7.1 Sanofi Company Details
    • 11.7.2 Sanofi Business Overview
    • 11.7.3 Sanofi Orphan Drugs Introduction
    • 11.7.4 Sanofi Revenue in Orphan Drugs Business (2017-2022)
    • 11.7.5 Sanofi Recent Development
  • 11.8 AstraZeneca
    • 11.8.1 AstraZeneca Company Details
    • 11.8.2 AstraZeneca Business Overview
    • 11.8.3 AstraZeneca Orphan Drugs Introduction
    • 11.8.4 AstraZeneca Revenue in Orphan Drugs Business (2017-2022)
  • 11.9 Takeda
    • 11.9.1 Takeda Company Details
    • 11.9.2 Takeda Business Overview
    • 11.9.3 Takeda Orphan Drugs Introduction
    • 11.9.4 Takeda Revenue in Orphan Drugs Business (2017-2022)
  • 11.10 Vertex Pharmaceuticals
    • 11.10.1 Vertex Pharmaceuticals Company Details
    • 11.10.2 Vertex Pharmaceuticals Business Overview
    • 11.10.3 Vertex Pharmaceuticals Orphan Drugs Introduction
    • 11.10.4 Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2017-2022)
  • 11.11 AbbVie
    • 11.11.1 AbbVie Company Details
    • 11.11.2 AbbVie Business Overview
    • 11.11.3 AbbVie Orphan Drugs Introduction
    • 11.11.4 AbbVie Revenue in Orphan Drugs Business (2017-2022)
    • 11.11.5 AbbVie Recent Development
  • 11.12 Biogen
    • 11.12.1 Biogen Company Details
    • 11.12.2 Biogen Business Overview
    • 11.12.3 Biogen Orphan Drugs Introduction
    • 11.12.4 Biogen Revenue in Orphan Drugs Business (2017-2022)
    • 11.12.5 Biogen Recent Development
  • 11.13 Eli Lilly
    • 11.13.1 Eli Lilly Company Details
    • 11.13.2 Eli Lilly Business Overview
    • 11.13.3 Eli Lilly Orphan Drugs Introduction
    • 11.13.4 Eli Lilly Revenue in Orphan Drugs Business (2017-2022)

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Disclaimer
  • 13.3 Author Details

LIST OF TABLES

  • Table 1. Global Orphan Drugs Market Size Growth Rate by Type (US$ Billion): 2017 VS 2021 VS 2028
  • Table 2. Global Orphan Drugs Market Size Growth by Application (US$ Billion): 2017 VS 2021 VS 2028
  • Table 3. Global Orphan Drugs Market Size by Region (US$ Billion): 2017 VS 2021 VS 2028
  • Table 4. Global Orphan Drugs Market Size by Region (2017-2022) & (US$ Billion)
  • Table 5. Global Orphan Drugs Market Share by Region (2017-2022)
  • Table 6. Global Orphan Drugs Forecasted Market Size by Region (2023-2028) & (US$ Billion)
  • Table 7. Global Orphan Drugs Market Share by Region (2023-2028)
  • Table 8. Orphan Drugs Market Trends
  • Table 9. Orphan Drugs Market Drivers
  • Table 10. Orphan Drugs Market Challenges
  • Table 11. Orphan Drugs Market Restraints
  • Table 12. Global Orphan Drugs Revenue by Players (2017-2022) & (US$ Billion)
  • Table 13. Global Orphan Drugs Market Share by Players (2017-2022)
  • Table 14. Global Top Orphan Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs as of 2021)
  • Table 15. Ranking of Global Top Orphan Drugs Companies by Revenue (US$ Billion) in 2021
  • Table 16. Global 5 Largest Players Market Share by Orphan Drugs Revenue (CR5 and HHI) & (2017-2022)
  • Table 17. Key Players Headquarters and Area Served
  • Table 18. Key Players Orphan Drugs Product Solution and Service
  • Table 19. Mergers & Acquisitions, Expansion Plans
  • Table 20. Global Orphan Drugs Market Size by Type (2017-2022) & (US$ Billion)
  • Table 21. Global Orphan Drugs Revenue Market Share by Type (2017-2022)
  • Table 22. Global Orphan Drugs Forecasted Market Size by Type (2023-2028) & (US$ Billion)
  • Table 23. Global Orphan Drugs Revenue Market Share by Type (2023-2028)
  • Table 24. Global Orphan Drugs Market Size by Application (2017-2022) & (US$ Billion)
  • Table 25. Global Orphan Drugs Revenue Market Share by Application (2017-2022)
  • Table 26. Global Orphan Drugs Forecasted Market Size by Application (2023-2028) & (US$ Billion)
  • Table 27. Global Orphan Drugs Revenue Market Share by Application (2023-2028)
  • Table 28. North America Orphan Drugs Market Size by Country (2017-2022) & (US$ Billion)
  • Table 29. North America Orphan Drugs Market Size by Country (2023-2028) & (US$ Billion)
  • Table 30. Europe Orphan Drugs Market Size by Country (2017-2022) & (US$ Billion)
  • Table 31. Europe Orphan Drugs Market Size by Country (2023-2028) & (US$ Billion)
  • Table 32. Asia-Pacific Orphan Drugs Market Size by Region (2017-2022) & (US$ Billion)
  • Table 33. Asia-Pacific Orphan Drugs Market Size by Region (2023-2028) & (US$ Billion)
  • Table 34. Latin America Orphan Drugs Market Size by Country (2017-2022) & (US$ Billion)
  • Table 35. Latin America Orphan Drugs Market Size by Country (2023-2028) & (US$ Billion)
  • Table 36. Middle East & Africa Orphan Drugs Market Size by Country (2017-2022) & (US$ Billion)
  • Table 37. Middle East & Africa Orphan Drugs Market Size by Country (2023-2028) & (US$ Billion)
  • Table 38. Bristol-Myers Squibb Company Details
  • Table 39. Bristol-Myers Squibb Business Overview
  • Table 40. Bristol-Myers Squibb Orphan Drugs Product
  • Table 41. Bristol-Myers Squibb Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 42. Bristol-Myers Squibb Recent Development
  • Table 43. Roche Company Details
  • Table 44. Roche Business Overview
  • Table 45. Roche Orphan Drugs Product
  • Table 46. Roche Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 47. Roche Recent Development
  • Table 48. Novartis Company Details
  • Table 49. Novartis Business Overview
  • Table 50. Novartis Orphan Drugs Product
  • Table 51. Novartis Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 52. Novartis Recent Development
  • Table 53. Johnson & Johnson Company Details
  • Table 54. Johnson & Johnson Business Overview
  • Table 55. Johnson & Johnson Orphan Drugs Product
  • Table 56. Johnson & Johnson Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 57. Pfizer Company Details
  • Table 58. Pfizer Business Overview
  • Table 59. Pfizer Orphan Drugs Product
  • Table 60. Pfizer Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 61. Pfizer Recent Development
  • Table 62. Amgen Company Details
  • Table 63. Amgen Business Overview
  • Table 64. Amgen Orphan Drugs Product
  • Table 65. Amgen Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 66. Amgen Recent Development
  • Table 67. Sanofi Company Details
  • Table 68. Sanofi Business Overview
  • Table 69. Sanofi Orphan Drugs Product
  • Table 70. Sanofi Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 71. Sanofi Recent Development
  • Table 72. AstraZeneca Company Details
  • Table 73. AstraZeneca Business Overview
  • Table 74. AstraZeneca Orphan Drugs Product
  • Table 75. AstraZeneca Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 76. Takeda Company Details
  • Table 77. Takeda Business Overview
  • Table 78. Takeda Orphan Drugs Product
  • Table 79. Takeda Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 80. Vertex Pharmaceuticals Company Details
  • Table 81. Vertex Pharmaceuticals Business Overview
  • Table 82. Vertex Pharmaceuticals Orphan Drugs Product
  • Table 83. Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 84. AbbVie Company Details
  • Table 85. AbbVie Business Overview
  • Table 86. AbbVie Orphan Drugs Product
  • Table 87. AbbVie Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 88. AbbVie Recent Development
  • Table 89. Biogen Company Details
  • Table 90. Biogen Business Overview
  • Table 91. Biogen Orphan Drugs Product
  • Table 92. Biogen Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 93. Biogen Recent Development
  • Table 94. Eli Lilly Company Details
  • Table 95. Eli Lilly Business Overview
  • Table 96. Eli Lilly Orphan Drugs Product
  • Table 97. Eli Lilly Revenue in Orphan Drugs Business (2017-2022) & (US$ Billion)
  • Table 98. Research Programs/Design for This Report
  • Table 99. Key Data Information from Secondary Sources
  • Table 100. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Orphan Drugs Market Share by Type: 2021 VS 2028
  • Figure 2. Global Orphan Drugs Market Share by Application: 2021 VS 2028
  • Figure 3. Orphan Drugs Report Years Considered
  • Figure 4. Global Orphan Drugs Market Size (US$ Billion), Year-over-Year: 2017-2028
  • Figure 5. Global Orphan Drugs Market Size, (US$ Billion), 2017 VS 2021 VS 2028
  • Figure 6. Global Orphan Drugs Market Share by Region: 2021 VS 2028
  • Figure 7. Global Orphan Drugs Market Share by Players in 2021
  • Figure 8. Global Top Orphan Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs as of 2021)
  • Figure 9. The Top 10 and 5 Players Market Share by Orphan Drugs Revenue in 2021
  • Figure 10. North America Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 11. United States Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 12. Canada Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 13. Europe Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 14. Germany Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 15. France Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 16. U.K. Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 17. Italy Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 18. Russia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 19. Nordic Countries Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 20. Asia-Pacific Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 21. China Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 22. Japan Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 23. South Korea Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 24. Southeast Asia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 25. India Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 26. Australia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 27. Latin America Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 28. Mexico Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 29. Brazil Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 30. Middle East & Africa Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 31. Turkey Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 32. Saudi Arabia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 33. UAE Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Billion)
  • Figure 34. Bottom-up and Top-down Approaches for This Report
  • Figure 35. Data Triangulation
  • Figure 36. Key Executives Interviewed